{
    "organizations": [],
    "uuid": "056405168544e27f119d74145c053d8c5cff7c70",
    "author": "",
    "url": "https://www.reuters.com/article/brief-abbvie-announces-positive-topline/brief-abbvie-announces-positive-topline-results-from-phase-3-study-evaluating-investigational-elagolix-in-women-with-uterine-fibroids-idUSFWN1QB0IM",
    "ord_in_thread": 0,
    "title": "BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 21, 2018 / 1:20 PM / Updated 3 minutes ago BRIEF-Abbvie Announces Positive Topline Results From Phase 3 Study Evaluating Investigational Elagolix In Women With Uterine Fibroids Reuters Staff 1 Min Read Feb 21 (Reuters) - Abbvie Inc: * ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 STUDY EVALUATING INVESTIGATIONAL ELAGOLIX IN WOMEN WITH UTERINE FIBROIDS * PHASE 3 ELARIS UF-I STUDY (M12-815) OF ELAGOLIX MET ITS PRIMARY ENDPOINT * RESULTS DEMONSTRATED ELAGOLIX, IN COMBINATION WITH LOW-DOSE ADD-BACK THERAPY, REDUCED HEAVY MENSTRUAL BLEEDING COMPARED TO PLACEBO * PHASE 3 ELARIS UF-I STUDY ALSO MET ALL RANKED SECONDARY ENDPOINTS (P<0.001) AT MONTH SIX Source text for Eikon: Further company coverage:",
    "published": "2018-02-21T15:18:00.000+02:00",
    "crawled": "2018-02-21T15:29:32.018+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "positive",
        "topline",
        "result",
        "phase",
        "study",
        "evaluating",
        "investigational",
        "elagolix",
        "woman",
        "uterine",
        "fibroid",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "abbvie",
        "inc",
        "abbvie",
        "announces",
        "positive",
        "topline",
        "result",
        "phase",
        "study",
        "evaluating",
        "investigational",
        "elagolix",
        "woman",
        "uterine",
        "fibroid",
        "phase",
        "elaris",
        "study",
        "elagolix",
        "met",
        "primary",
        "endpoint",
        "result",
        "demonstrated",
        "elagolix",
        "combination",
        "therapy",
        "reduced",
        "heavy",
        "menstrual",
        "bleeding",
        "compared",
        "placebo",
        "phase",
        "elaris",
        "study",
        "also",
        "met",
        "ranked",
        "secondary",
        "endpoint",
        "p",
        "month",
        "six",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}